A5045090879- Asthma and respiratory diseases
- Pharmaceutical studies and practices
- Respiratory and Cough-Related Research
- Inhalation and Respiratory Drug Delivery
- Allergic Rhinitis and Sensitization
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Antibiotics Pharmacokinetics and Efficacy
- Pharmacological Effects and Assays
- Cystic Fibrosis Research Advances
- Pharmacological Effects and Toxicity Studies
- Poisoning and overdose treatments
- Epilepsy research and treatment
- Analytical Methods in Pharmaceuticals
- Pharmaceutical Practices and Patient Outcomes
- Ion channel regulation and function
- Pharmaceutical Economics and Policy
- Pneumonia and Respiratory Infections
- Pharmacology and Obesity Treatment
- Cancer Treatment and Pharmacology
- Child Nutrition and Feeding Issues
- Reproductive tract infections research
- Receptor Mechanisms and Signaling
- Pharmacogenetics and Drug Metabolism
- Pediatric health and respiratory diseases
- Emergency and Acute Care Studies
University of Florida
2014-2025
Florida College
1993-2020
Columbus Oncology and Hematology Associates
2018
Pulmonary Associates
2011
American Association of Colleges of Pharmacy
2003-2007
University of Iowa
1980-2006
UF Health Shands Hospital
1987-2006
Pediatrics and Genetics
2004
University of Florida Health
2001-2002
Merck & Co., Inc., Rahway, NJ, USA (United States)
1997-1999
Patients with mild asthma frequently have only exercise-induced bronchoconstriction, a symptom of inadequate control asthma. We evaluated the ability montelukast, leukotriene-receptor antagonist, to protect such patients against bronchoconstriction.
Leukotrienes are pro-inflammatory mediators which may contribute to tissue, sputum, and blood eosinophilia seen in allergic inflammatory diseases, including asthma. Montelukast is a cysteinyl leukotriene1 (CysLT1) receptor antagonist improves asthma control; the aim of this study was investigate its effect on induced sputum eosinophils. 10 mg (n=19) or placebo (n=21) were administered orally once evening for 4 weeks 40 chronic adult asthmatic patients, aged 19-64 yrs, double-blind,...
To assess the potential for therapeutic problems related to bioavailability of oral theophylline preparations, we examined rate and extent absorption various formulations in adult volunteers. Absorption from a solution or uncoated tablets was rapid complete. Three six sustained-release were more slowly, but still completely consistently, absorbed. other three appeared be erratic less Serum concentration-time curves during multiple eight-hour dosing simulated bioavailable preparations. With...
BACKGROUND: A study was undertaken to determine whether montelukast, a new potent cysteinyl leukotriene receptor antagonist, attenuates exercise-induced bronchoconstriction. The relationship between the urinary excretion of LTE4 and bronchoconstriction also investigated. METHODS: Nineteen non-smoking asthmatic patients with forced expiratory volume in one second (FEV1) > or = 65% predicted value reproducible fall FEV1 after exercise at least 20% were enrolled. Subjects received placebo...
The Rationale for Slow-Release TheophyllineIn 1974 a report of placebo-controlled double-blind crossover study indicated that treatment with theophylline was associated dramatic decrease in symptoms and signs chronic asthma without adverse effects when used individualized doses maintained serum concentrations between 10 20 μg per milliliter; approximated previous customary usage produced lower were not effective reducing symptoms.1 Although some bronchodilatory effect occurs at...
Use of recommended IV aminophylline dosage regimens in 48 older, acutely ill, hospitalized patients with chronic obstructive pulmonary disease (COPD) resulted excessive plasma theophylline concentrations 29 percent these patients. A mean dose 0.89 mg/kg/hr produced a concentration which ranged from 7 to 52 mcg/ml 21.9 mcg/ml. Plasma was determined spectrophotometrically samples drawn at least 12 hours after loading and initiation constant infusion. Severity toxicity strongly correlated the...
The absolute bioavailability of theophylline was investigated by comparing the areas under concentration-time curves for intravenous with a plain uncoated anhydrous tablet and solution. Twenty asthmatic adults received approximately 7.5 mg/kg intravenously over 30 minutes; either seven days before or after i.v. dose, 10 these patients tablets remainder solution in similar dose. Blood samples were obtained at 0, 10, 20, 30, 45, 60, 90, 120, 180 240 minutes then every two hours least 12 hours....
Use of recommended IV aminophylline dosage regimens in 48 older, acutely ill, hospitalized patients with chronic obstructive pulmonary disease (COPD) resulted excessive plasma theophylline concentrations 29 percent these patients. A mean dose 0.89 mg/kg/hr produced a concentration which ranged from 7 to 52 mcg/ml 21.9 mcg/ml. Plasma was determined spectrophotometrically samples drawn at least 12 hours after loading and initiation constant infusion. Severity toxicity strongly correlated the...
This March 2009 Workshop Summary Report was sponsored by Product Quality Research Institute (PQRI) based on a proposal the Inhalation and Nasal Technology Focus Group (INTFG) of American Association Pharmaceutical Scientists (AAPS). Participants from pharmaceutical industry, academia regulatory bodies United States, Europe, India, Brazil attended workshop with objective presenting, reviewing, discussing recommendations for demonstrating bioequivalence (BE) that may be considered in...
Theophylline serum concentration and disposition after a single 30-min intravenous infusion of 7.4 ± 1 mg anhydrous theophylline per kg body weight were determined in 20 otherwise healthy adult asthmatic volunteers using high-pressure cation-exchange chromatography. This dose resulted mean peak 18 3.3 μg ml, which remained > 10 ml for 6 hours 5 the entire 12-hour period observation. The rate elimination these subjects was generally slower than previously reported. Among 4 cigarette smokers,...